A multicenter, open-label study for efficacy and safety evaluation of anagrelide in patients with treatment-naïve, high-risk essential thrombocythemia as a primary treatment

As the discussion of first-line anagrelide treatment is ongoing, we aimed to prospectively examine the efficacy and safety of anagrelide in cytoreduction therapy-naïve high risk essential thrombocythemia (ET) patients in Korea. Seventy patients from 12 centers were treated with anagrelide monotherap...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Ja Min, Kim, Ho Young, Nam, Seung-Hyun, Shin, Ho-Jin, Song, Seulki, Park, Jinny, Han, Sang Hoon, Park, Yong, Yuh, Young Jin, Mun, Yeung-Chul, Do, Young Rok, Sohn, Sang Kyun, Bae, Sung Hwa, Shin, Dong-Yeop, Yoon, Sung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727180/
https://www.ncbi.nlm.nih.gov/pubmed/36505839
http://dx.doi.org/10.3389/fonc.2022.989984

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9727180/
https://www.ncbi.nlm.nih.gov/pubmed/36505839
http://dx.doi.org/10.3389/fonc.2022.989984

Ejemplares similares